Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly Poised To Lead In Alzheimer’s, But Success Depends On Solanezumab

Executive Summary

Lilly's comprehensive R&D initiative to lead in Alzheimer’s disease includes seven drugs in or nearing the clinic, with an eye on combinations. But until data from a third Phase III trial testing solanezumab read out in late 2016/early 2017, investors remain skeptical.

Advertisement

Related Content

Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Spotlight Returns To Biogen R&D To Sustain Success
Lilly Back In The BACE Space Following Deal With AstraZeneca
Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely
A Silver Lining In Lilly’s Solanezumab Alzheimer’s Failure?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register